Related Experiment Videos
Biological therapy in Crohn's disease
1Division of Infection, Inflammation, and Repair, University of Southampton, Southampton General Hospital, Southampton, SO16 6YD.
Hospital Medicine (London, England : 1998)
|January 2, 2004
Summary
Tumour necrosis factor-alpha (TNF-α) is central to Crohn's disease treatment. New biological therapies targeting immune pathways offer future treatment advancements for refractory cases.
Area of Science:
- Immunology
- Gastroenterology
- Pharmacology
Background:
- Crohn's disease is an inflammatory bowel disease with complex immunopathology.
- Tumour necrosis factor-alpha (TNF-α) has been identified as a key mediator in Crohn's disease pathogenesis.
Purpose of the Study:
- To highlight the impact of TNF-α targeted therapy on Crohn's disease.
- To discuss the future development of novel biological therapies for Crohn's disease.
Main Methods:
- Review of clinical practice and therapeutic advancements.
- Analysis of immunopathological research in Crohn's disease.
Main Results:
- Infliximab, a TNF-α inhibitor, has revolutionized the treatment of refractory Crohn's disease.
- Understanding immune pathways is driving the development of new biological agents.
Conclusions:
- TNF-α blockade represents a significant therapeutic advance in Crohn's disease management.
- Future research in immunopathology will likely yield more targeted and effective biological therapies for Crohn's disease.